Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

BUY
$2.12 - $2.76 $233,200 - $303,600
110,000 Added 39.29%
390,000 $846,000
Q1 2021

May 13, 2021

BUY
$0.94 - $3.31 $263,200 - $926,800
280,000 New
280,000 $630,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.66B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Stelac Advisory Services LLC Portfolio

Follow Stelac Advisory Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stelac Advisory Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stelac Advisory Services LLC with notifications on news.